George Tidmarsh, the director of the FDA's Center for Drug Evaluation and Research (CDER), has been appointed as the acting director of the Center for Biologics Evaluation and Research (CBER) following the abrupt resignation of Vinay Prasad. Tidmarsh will oversee both centers temporarily, with Scott Steele and Brittany Goldberg serving as deputy directors at CBER. Prasad's departure came amid controversy surrounding Sarepta Therapeutics and its drug, which faced scrutiny after the death of patients and pressure from the FDA. Sarepta engaged the political consulting firm Michael Best Strategies, which recently hired political influencer Chris LaCivita. This was followed by a series of media attacks on Prasad, who was known for his anti-corruption stance and efforts to reform the FDA. His exit has been characterized by some as the result of collusion between Sarepta and online critics. Prasad had accepted the FDA role understanding the challenges involved but was removed quickly amid the ongoing disputes.